For our partners, the Russian pharmaceutical market is a market of new business development opportunities and NovaMedica is a reliable guide in entering it. For the last decade, the Russian pharma market has been steadily growing in general and especially in those therapeutic areas where there were previously unmet needs. These areas see the most active growth and still have unoccupied market niches.
The key therapeutic areas with the highest potential for partnership and business development in Russia are diseases of the central nervous system (CNS) and rare diseases (orphan products). Our advanced commercial infrastructure, successful history of product licensing and commercialization, experience in cooperation with international companies, as well as our own R&D and manufacturing site will provide a sound bridge for our partners to enter the Russian market.
For the last decade, the Russian market has demonstrated rapid growth, and experts believe that this trend will persist.
According to the data of IQVIA analysts for 2020, the Russian pharma market grew by 16% (to 1,554 bln rubles) in value vs. 2019. In the same period, the retail market grew by 10% (to 939 bln rubles), and the hospital segment (not including federal and regional drug reimbursement programs) – by 37% (to 353 bln rubles). Federal drug reimbursement increased by 9.4% (to 124 bln rubles), and regional drug reimbursement – by 23% (to 138 bln rubles).
The CNS area, a target market for NovaMedica and our potential partners, shows stable growth in the retail segment annually increasing by 6-7% in value. In 2020, it totaled 115 bln rubles, with oral forms taking a dominant position. The most important trends here are the increasing number of patients and replacement of outdated cheap products with more expensive improved options.
The orphan market, the second target segment where we are looking for partners, has been steadily growing in Russia by 17% per year on average for the last five years, which is due to very important positive changes in the Russian legislation and to expansion of state support for the treatment of rare diseases.
No other therapeutic area can boast such rapid development. In 2021, upon the initiative of the President of Russia Vladimir Putin, the State Foundation Circle of Kindness was created to help children with severe, including orphan, diseases. The State intends to provide 60 bln rubles to finance the Foundation’s activities. About 25 bln rubles has already been provided, and the Foundation used this money to fund the treatment of 1,345 little patients.*1
The State’s close attention to the sector gave a new impulse to development of this market. One could expect that in the next five year the orphan segment will maintain its high growth rates and that new diseases and products will be included in the priority lists for state support, which creates opportunities for efficient work in this area. NovaMedica Rare Disease Initiative, the special project within NovaMedica, is targeted for development in this extremely potential segment.
(*1) - Circle of Kindness Foundation
For almost ten years, NovaMedica has been using the opportunities of the Russian growing pharmaceutical market to build its portfolio, and invites partners interested in promoting their products in Russia to share in our success.
To our partners, we offer a package of services that is as customized as possible and that includes all necessary product promotion stages, from clinical trials to market launch and sales organization. NovaMedica has the entire range of capabilities to ensure high-quality support of its partners at each stage. We have everything required for successful cooperation:
We are ready to contribute all these to joint projects with our partners to pave the way to success in the Russian market together.
26 October 2021
26 October 2021
26 October 2021
25 October 2021